SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (520)11/5/2005 2:29:12 PM
From: keokalani'nui  Read Replies (1) of 590
 
Yes, 'blinded' is preferred for PFS according to the guidance. But Permutter--famous last words--said they talked about this design with FDA before trial started and after when I assume they made some changes potentially affecting bias. And the readings that I understand to be the basis for the EP in fact were made centrally and were blinded.

I'm not saying at all this is an SPA. And I do think temptation to wait not very long for survival data will be irresistable.

And I do not have big stake in outcome anyway!

(Edit: Just saw your post re BSC crossover. You are surely very close with assumptions and conclusions. Nice comment about tarceva KM too. Thanks.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News